Last reviewed · How we verify
0.005% Latanoprost
0.005% Latanoprost, marketed by Otsuka Beijing Research Institute, holds a position in the glaucoma treatment market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | 0.005% Latanoprost |
|---|---|
| Also known as | 0.005% Latanoprost ophthalmic solution |
| Sponsor | Otsuka Beijing Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.005% Latanoprost CI brief — competitive landscape report
- 0.005% Latanoprost updates RSS · CI watch RSS
- Otsuka Beijing Research Institute portfolio CI